Publication AWA

At the Public Information Bulletin of the Agency for Health Technology Assessment and Tariff System (AWA) has published reviews analyses for the evaluation of reimbursement applications:

• Apixaban (apixabanum) for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation who have at least one risk factor, such as a history of stroke or transient ischemic attack; age ≥ 75 years; hypertension; diabetes; symptomatic heart failure
• Embavi (apixabanum) for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and at least one risk factor, such as: prior stroke or transient ischemic attack; age ≥ 75 years; hypertension; diabetes; symptomatic heart failure

We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.